By:
On:
In: Actions

On Tuesday April 9, 2024, the Union for Affordable Cancer Treatment (UACT), Knowledge Ecology International (KEI), and Universities Allied for Essential Medicines (UAEM) requested that the Centers for Medicare and Medicaid Services (CMS) use the rights afforded to the government in 35 U.S.C. § 202 and 28 U.S.C. § 1498 on patents on the prostate cancer drug Xtandi (enzalutamide). As noted in the request letter, “The U.S. government has a “world wide nonexclusive, nontransferrable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any subject invention throughout the world” (35 USC § 202(c)(4)). This worldwide paid-up license canRead More →

By:
On:
In: Actions

Today, Kayla Gu, MS1 at UCLA spoke to the University of California Board of Regents on behalf of Universities Allied for Essential Medicines (UAEM), Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT). She urged UCLA to drop the patent claim in India on enzalutamide (Xtandi) that would bar affordable access to a lifesaving prostate cancer drug. Kayla knows the story of Xtandi quite well: she presented on the topic at Los Angeles Global Health Conference 2018: Looking In, Looking Out: Balancing Global and Local Priorities in the Current Political Climate on February 3, 2018 and in the following blog: The StoryRead More →